Abstract:AIM:To evaluate the effect of postoperative adjuvant transcatheter arterial chemoembolization (TACE) on the prognosis of hepatocellular carcinoma (HCC) patients with or without risk factors for the residual tumor.METHODS:From January 1995 to December 1998, 549 consecutive HCC patients undergoing surgical resection were included in this research. There were 185 patients who underwent surgical resection with adjuvant TACE and 364 patients who underwent surgical resection only. Tumors with a diameter more than 5 cm, multiple nodules, and vascular invasion were defined as risk factors for residual tumor and used for patient stratification. Kaplan-Meier method was used to analyze survival curve and Cox proportional hazard model was used to evaluate the prognostic significance of adjuvant TACE.RESULTS:In the patients without any risk factors for the residual tumor, the 1-, 3-, 5-year survival rates were 93.48%, 75.85%, 62.39% in the control group and 97.39%, 70.37%, 50.85% in the adjuvant TACE group, respectively. There was no significant difference in the survival between two groups (P = 0.3956). However, in the patients with risk factors for residual tumor, postoperative adjuvant TACE significantly prolonged the patients' survival. There was a statistically significant difference in survival between two groups (P = 0.0216). The 1-, 3-, 5-year survival rates were 69.95%, 49.86%, 37.40% in the control group and 89.67%, 61.28%, 44.36% in the adjuvant TACE group, respectively. Cox proportional hazard model showed that tumor diameter and cirrhosis, but not the adjuvant TACE, were the significantly independent prognostic factors in the patients without risk factors for residual tumor. However, in the patients with risk factors for residual tumor adjuvant TACE, and also tumor diameter, AFP level, vascular invasion, were the significantly independent factors associated with the decreasing risk for patients' death from HCC.CONCLUSION:Postoperative adjuvant TACE can prolong the survival of patients with risk factors for residual tumor, but can not prolong the survival of patients without risk factors for residual tumor.

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study.

Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis

Adjuvant Transarterial Chemoembolization Does Not Influence Recurrence-free and Overall Survivals for Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma after Curative Resection: a Propensity Score Matching Analysis

Hepatic Resection for Hepatocellular Carcinoma with or Without Postoperative Adjuvant Transarterial Chemoembolization: a Comparative Study

Adjuvant TACE May Not Improve Recurrence-Free or Overall Survival in HCC Patients with Low Risk of Recurrence after Hepatectomy

Adjuvant transarterial chemoembolization to improve the prognosis of hepatocellular carcinoma following curative resection

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China

Postoperative Adjuvant Arterial Chemoembolization Improves Survival of Hepatocellular Carcinoma Patients with Risk Factors for Residual Tumor: a Retrospective Control Study.

Transarterial Chemoembolization As an Adjuvant Therapy in Patients with Hepatocellular Carcinoma Treated with Hepatectomy

Adjuvant Transcatheter Arterial Chemoembolization after Radical Resection of Hepatocellular Carcinoma Patients with Tumor Size Less Than 5 Cm: a Retrospective Study

Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma after Radical Hepatectomy: a Real World Study.

Transcatheter Arterial Chemoembolization Alone or Combined with Ablation for Recurrent Intermediate-Stage Hepatocellular Carcinoma: a Propensity Score Matching Study

Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-term Survival and Recurrence in Patients with Resectable Huge Hepatocelluar Carcinoma A Multicentre Retrospective Analysis

Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy

Adjuvant Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy

Survival Analysis of 53 Patients with Hepatocellular Carcinoma Undergoing Adjuvant Transcatheter Arterial Chemoembolization after Radical Resection

Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization

Who Can Benefit from Adjuvant Transcatheter Arterial Chemoembolization after Surgical Resection of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis

Repeated Postoperative Adjuvant TACE after Curative Hepatectomy Improves Outcomes of Patients with HCC